|
|
|
|
|
|
Sponsors and Collaborators: |
Eli Lilly and Company ICOS Corporation |
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00157326 |
Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderate hypertension.
Condition | Intervention | Phase |
Hypertension |
Drug: tadalafil |
Phase II |
MedlinePlus related topics: | High Blood Pressure |
ChemIDplus related topics: | Tadalafil |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension |
Enrollment: | 180 |
Study Start Date: | September 2005 |
Study Completion Date: | June 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Washington | |||||
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |||||
Bothell, Washington, United States |
Eli Lilly and Company |
ICOS Corporation |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Lilly Clinical Trial Registry 
  |
Study ID Numbers: | 10077, H6D-MC-LVGU |
First Received: | September 8, 2005 |
Last Updated: | October 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00157326 |
Health Authority: | United States: Food and Drug Administration; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|